CPT 81361 HBB Variant Test Reimbursement

CPT code 81361 represents a molecular diagnostic laboratory test that detects common variants in the hemoglobin, subunit beta (HBB) gene, including HbS, HbC, and HbE. This diagnostic code is used nationally to document the technical laboratory procedure that identifies clinically important hemoglobinopathy variants, which can inform diagnosis, carrier screening, and clinical management decisions.

Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for HBB variant testing, typical sites of service, and the role this test plays in diagnosing sickle cell disease and other hemoglobinopathies. The publication summarizes common billing considerations, relevant modifiers, and expected service line placement where available.

The report provides benchmarks and policy-relevant updates for payers and laboratory billing teams, clarifies coding usage for the technical component of HBB variant detection, and outlines how this test fits into broader genetic and hematology testing workflows. Data not available in the input are noted where applicable.

Billing Code Overview

CPT code 81361 describes a laboratory molecular test that detects specific variants in the hemoglobin, subunit beta (HBB) gene, such as HbS, HbC, and HbE. The service involves a technical laboratory procedure to identify common HBB gene changes associated with hemoglobinopathies.

Service type: Molecular diagnostic laboratory test

Typical site of service: Clinical laboratory or hospital laboratory, including reference lab settings

Clinical Context

A 6-year-old child of African descent presents to a pediatric hematology clinic after newborn screening suggested abnormal hemoglobin traits and the family reports a history of recurrent mild anemia and episodic pain. The clinician orders molecular testing for common beta-globin (HBB) gene variants to identify sickle cell (HbS), hemoglobin C (HbC), or hemoglobin E (HbE) variants. A specimen (EDTA whole blood) is collected in clinic and sent to the molecular diagnostics laboratory. The laboratory performs 81361 testing using targeted DNA analysis methods (such as allele-specific PCR or targeted sequencing) to detect the presence of common HBB variants. Results reporting includes detected variant(s), zygosity (heterozygous/compound/ homozygous), and an interpretation for the ordering clinician. Typical workflow steps: order entry on the electronic medical record, specimen collection and labeling, accessioning in the lab, DNA extraction, targeted variant testing, result validation by a laboratory director, and final report release. Typical site of service: outpatient clinic or ambulatory laboratory collection with testing performed in a clinical molecular diagnostics laboratory affiliated with a hospital or commercial reference lab. Common payors for coverage considerations include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare.

Coding Specifications

Modifier	Description	When to Use
`26`	Professional component

Taxonomy Code	Specialty	Notes
207Q00000X	Hematology	Physicians who evaluate and order hemoglobinopathy testing.
207RH0000X	Pediatric Hematology-Oncology	Specialists who commonly manage sickle cell disease and order molecular HBB testing.
207LP2900X	Clinical Pathology	Pathologists and laboratory directors who oversee molecular diagnostic testing.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`D57.0`	Sickle-cell disease with crisis	Molecular HBB testing identifies HbS variants that confirm sickle cell disease and guide management.
`D57.1`	Sickle-cell disease without crisis	Variant detection assists in diagnosis and genetic counseling.
`D57.8`	Other sickle-cell disorders	Used when non-specific sickle-cell presentations require molecular confirmation.
`D57.9`	Sickle-cell disease, unspecified	Applied when documentation lacks specificity; testing clarifies genotype.
`D56.9`	Thalassemia, unspecified	Beta-globin variants can underlie thalassemia traits; molecular testing helps differentiate.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`81240`	Hemoglobin, beta chain (HBB); full gene sequencing	Performed when targeted variant testing (`81361`) is negative or when full gene sequencing is needed for rare or novel variants.
`83020`	Hemoglobin electrophoresis (including quantitation, if performed)	Often performed as a first-line screening test to identify abnormal hemoglobin patterns before molecular confirmation with `81361`.
`36415`	Collection of venous blood by venipuncture	Specimen collection code used when obtaining blood for the molecular test.
`81002`	Urinalysis, non-automated, without microscopy	(Supportive lab test) Sometimes ordered in baseline evaluation but not specific to HBB testing.

OpenPayer

Summary & Overview

CPT 81361: HBB Gene Variant Testing for HbS/HbC/HbE